Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study (2021)

First Author: Khoo S
Attributed to:  New Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/jac/dkab318

Publication URI: http://dx.doi.org/10.1093/jac/dkab318

Type: Journal Article/Review

Parent Publication: Journal of Antimicrobial Chemotherapy

Issue: 12